These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 28550595)
21. Colistin: an update on the antibiotic of the 21st century. Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331 [TBL] [Abstract][Full Text] [Related]
22. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. Mohamed AF; Cars O; Friberg LE J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic evaluation of colistin sodium. Michalopoulos AS; Karatza DC; Gregorakos L Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824 [TBL] [Abstract][Full Text] [Related]
26. Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria. Imberti R; Iotti GA; Regazzi M Expert Rev Anti Infect Ther; 2014 Apr; 12(4):471-8. PubMed ID: 24597575 [TBL] [Abstract][Full Text] [Related]
27. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. Kristoffersson AN; Rognås V; Brill MJE; Dishon-Benattar Y; Durante-Mangoni E; Daitch V; Skiada A; Lellouche J; Nutman A; Kotsaki A; Andini R; Eliakim-Raz N; Bitterman R; Antoniadou A; Karlsson MO; Theuretzbacher U; Leibovici L; Daikos GL; Mouton JW; Carmeli Y; Paul M; Friberg LE Clin Microbiol Infect; 2020 Dec; 26(12):1644-1650. PubMed ID: 32213316 [TBL] [Abstract][Full Text] [Related]
29. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668 [TBL] [Abstract][Full Text] [Related]
30. Multidrug-resistant Gram-negative infections: the use of colistin. Michalopoulos AS; Karatza DC Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945 [TBL] [Abstract][Full Text] [Related]
31. Colistin: understanding and applying recent pharmacokinetic advances. Ortwine JK; Kaye KS; Li J; Pogue JM Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study. Gautam V; Shafiq N; Mouton JW; Malhotra S; Kaur S; Ray P Indian J Med Res; 2018 Apr; 147(4):407-412. PubMed ID: 29998877 [TBL] [Abstract][Full Text] [Related]
33. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Kassamali Z; Danziger L Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395 [TBL] [Abstract][Full Text] [Related]
34. Colistin: an antibiotic and its role in multiresistant Gram-negative infections. Loho T; Dharmayanti A Acta Med Indones; 2015 Apr; 47(2):157-68. PubMed ID: 26260559 [TBL] [Abstract][Full Text] [Related]
35. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside. Zavascki AP Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154 [TBL] [Abstract][Full Text] [Related]
37. Colistin Area Under the Time-Concentration in Children Treated With Intravenous Loading Dose and Maintenance Therapy. Mesini A; Loy A; Gattorno M; Moscatelli A; Bandettini R; Faraci M; Cangemi G; Castagnola E Clin Infect Dis; 2018 Feb; 66(5):808-809. PubMed ID: 29020309 [No Abstract] [Full Text] [Related]
38. Colistin: Revival of an Old Polymyxin Antibiotic. Dijkmans AC; Wilms EB; Kamerling IM; Birkhoff W; Ortiz-Zacarías NV; van Nieuwkoop C; Verbrugh HA; Touw DJ Ther Drug Monit; 2015 Aug; 37(4):419-27. PubMed ID: 25549206 [TBL] [Abstract][Full Text] [Related]
39. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445 [TBL] [Abstract][Full Text] [Related]